Mobile Site ›

Autoantibody Profiles of Myasthenia Gravis, Thymoma & Lambert-Eaton Myasthenic Syndrome


Receive notification when new Hot Topics are published:

Reasons to Discontinue Testing for AChR Blocking Antibody

Slide 15

July 2009

So previously a test that measured acetylcholine receptor blocking antibodies alone was offered, but this was to be found of minimal clinical utility because the antibody only measures the acetylcholine receptor blocking antibody; whereas, the acetylcholine receptor modulating antibody test detects both modulating and blocking antibodies. The sole clinical utility of the blocking antibody is that it is generally detected in patients who have very severe myasthenia gravis with severe generalized weakness. However, the blocking antibody alone is never positive when the acetylcholine receptor binding and modulating antibody tests are negative. There is no additional information gained from this test for assessing thymoma risk in patients with myasthenia gravis. Therefore, the test is not cost effective.

Reasons to Discontinue Testing


Jump to section: